Method for manufacturing a membrane for guided bone regeneration

A membrane manufacturing method using alginate-catechol and calcium ions with protein coating addresses the challenge of controlled growth factor release, enhancing bone regeneration by forming a biocompatible and structurally stable membrane that promotes bone tissue growth.

KR103047100B1Active Publication Date: 2026-11-11KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020260003970
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2026-01-09
Publication Date
2026-11-11
Estimated Expiration
2046-01-09

AI Technical Summary

Technical Problem

Conventional biodegradable GBR membranes do not effectively release growth factors like BMP-2, limiting their bone regeneration effect, and there is a need for membranes that can gradually release such factors while providing enhanced bone tissue-induced regeneration.

Method used

A method involving the preparation of an electrospinning solution with alginate modified with catechol functional groups, polyethylene oxide, and Triton X-100, electrospinning this solution to form an alginate-catechol membrane, cross-linking it with calcium ions, and coating it with proteins like BMP-2 to create a membrane that gradually releases growth factors.

Benefits of technology

The resulting membrane achieves gradual release of growth factors, enhancing bone tissue regeneration with improved mechanical properties and biocompatibility, maintaining structural integrity and promoting bone formation without inducing inflammation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112026003116014-PAT00014_ABST
    Figure 112026003116014-PAT00014_ABST
Patent Text Reader

Abstract

The present invention relates to a method for manufacturing a membrane for inducing bone tissue regeneration, and more specifically, to a method for manufacturing a membrane for inducing bone tissue regeneration characterized by spinning an electrospinning solution containing alginate modified with catechol functional groups onto a membrane to produce an alginate-catechol membrane, immersing the alginate-catechol membrane in a calcium chloride solution to produce an alginate-catechol membrane cross-linked with calcium ions, and coating a protein onto the alginate-catechol membrane cross-linked with calcium ions. The present invention can provide a method for manufacturing a membrane that gradually releases growth factors while having an excellent bone tissue-induced regeneration effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a method for manufacturing a membrane for inducing bone tissue regeneration, and more specifically, to a method for manufacturing a membrane for inducing bone tissue regeneration characterized by spinning an electrospinning solution containing alginate modified with catechol functional groups onto a membrane to produce an alginate-catechol membrane, immersing the alginate-catechol membrane in a calcium chloride solution to produce an alginate-catechol membrane cross-linked with calcium ions, and coating a protein onto the alginate-catechol membrane cross-linked with calcium ions. Background Technology

[0002] Guided bone regeneration (GBR), a widely used strategy for bone defects, is a method that uses a physical membrane to prevent rapidly growing soft tissue from invading the bone defect, thereby creating and maintaining a separated space that allows osteoblasts to differentiate more effectively without interference.

[0003] GBR membranes are classified into absorbable and non-absorbable types; however, since non-absorbable GBR membranes must be removed through secondary surgery, absorbable membranes are receiving more attention than non-absorbable membranes. Conventional biodegradable GBR membranes perform well as a barrier membrane to provide space, but they have limitations in that the bone regeneration effect is not as pronounced as that of membranes treated with growth factors.

[0004] Therefore, recently, there has been a growing need for membranes that can not only function as a barrier but also further enhance bone regeneration in bone defect areas. To this end, much attention is being focused on developing GBR membranes loaded with growth factors that biologically activate bone formation.

[0005] In particular, among bone formation factors, bone morphogenic protein 2 (BMP-2) is a protein that plays a very important role in bone formation, as revealed in studies of transgenic mice. However, conventional studies have limitations in controlling the release of BMP-2 because growth factors are physically loaded. Therefore, there is a growing need for a membrane that can gradually release growth factors while also providing excellent bone tissue-induced regeneration effects. Prior art literature

[0006] Republic of Korea Registered Patent Publication No. 10-1803741 The problem to be solved

[0007] The objective of the present invention is to provide a method for manufacturing a membrane that gradually releases growth factors while having an excellent bone tissue-induced regeneration effect.

[0008] The technical problems that the invention aims to solve are not limited to those mentioned above, and other unmentioned technical problems can be clearly understood by those skilled in the art from the description of the invention. means of solving the problem

[0009] The present invention provides a method for manufacturing a membrane for inducing bone tissue regeneration, comprising the steps of: preparing an electrospinning solution; electrospinning the electrospinning solution onto a membrane to produce an alginate-catechol membrane; immersing the alginate-catechol membrane in a calcium chloride solution to produce an alginate-catechol membrane cross-linked with calcium ions; and coating a protein onto the alginate-catechol membrane cross-linked with calcium ions.

[0010] In the present invention, the electrospinning solution is characterized by comprising alginate modified with catechol functional groups (Alginate-catechol); polyethylene oxide; ethanol; and Triton X-100.

[0011] In the present invention, the electrospinning solution is characterized by comprising, for every 0.2 parts by weight of polyethylene oxide, 0.1 to 4 parts by weight of alginate modified with catechol functional groups; 2 to 12 parts by weight of ethanol; and 0.1 to 1 part by weight of Triton X-100.

[0012] In the present invention, the step of preparing the alginate-catechol membrane is characterized by electrospinning the electrospinning solution at a flow rate of 0.1 to 1 mL / h.

[0013] In the present invention, the step of preparing the alginate-catechol membrane is characterized by electrospinning the electrospinning solution at a voltage of 15 to 25 kV.

[0014] In the present invention, the step of preparing the alginate-catechol membrane is characterized by electrospinning under conditions of a temperature of 21 to 31°C and a relative humidity of 25 to 45%.

[0015] In the present invention, the step of manufacturing the alginate-catechol membrane is characterized by electrospinning at a spinning distance of 10 to 20 cm.

[0016] In the present invention, the step of preparing an alginate-catechol membrane cross-linked with calcium ions is characterized by immersing the alginate-catechol membrane in a solution in which calcium chloride (CaCl2) is mixed with a solvent in a volume ratio of ethanol and distilled water of 1:3 to 7.

[0017] In the present invention, the solution in which calcium chloride (CaCl2) is mixed with a solvent in which ethanol and distilled water are mixed in a volume ratio of 1:3 to 7 is characterized by mixing calcium chloride at a concentration of 0.1 to 4 wt% with the solvent in which ethanol and distilled water are mixed in a volume ratio of 1:3 to 7.

[0018] In the present invention, the step of preparing an alginate-catechol membrane cross-linked with calcium ions further comprises the step of washing the alginate-catechol membrane with one or more solvents selected from the group consisting of distilled water and methanol.

[0019] In the present invention, the step of coating a protein on the calcium ion-crosslinked alginate-catechol membrane is characterized by coating the calcium ion-crosslinked alginate-catechol membrane with one or more proteins selected from the group consisting of BMP-2 (Bone morphogenetic protein-2); BSA (Bovine serum albumin); HSA (Human serum albumin); Gelatin; a protein conjugated with fluorescein isothiocyanate (FITC); and BSA conjugated with FITC. Effects of the invention

[0020] The present invention can provide a method for manufacturing a membrane that gradually releases growth factors while having an excellent bone tissue-induced regeneration effect.

[0021] The effects of the present invention are not limited to those mentioned above, and other unmentioned effects will be clearly understood by those skilled in the art from the description in the claims. Brief explanation of the drawing

[0022] FIG. 1 is a schematic diagram showing a method for manufacturing a membrane for inducing bone tissue regeneration according to the present invention. Figure 2 is a figure showing an SEM image of the membrane for inducing bone tissue regeneration according to the present invention. Figure 3 is a figure showing the results of FT-IR analysis of the components constituting the bone tissue regeneration-inducing membrane of the present invention. Figure 4 is a figure showing the results of analyzing the mechanical properties of the membrane for inducing bone tissue regeneration according to the present invention. Figure 5 is a figure showing the results of analyzing the cell compatibility and bone formation inducing ability of the membrane for inducing bone tissue regeneration according to the present invention. Figure 6 is a figure showing the results of analyzing the protein adsorption rate according to the type of protein coated on the membrane for inducing bone tissue regeneration according to the present invention. Figure 7 is a figure showing the results of analyzing the protein adsorption rate when FITC-BSA is coated on the bone tissue regeneration-inducing membrane of the present invention. Figure 8 is a figure showing the results of analyzing the phosphorylation enzyme activity of the membrane for inducing bone tissue regeneration according to the present invention. Figure 9 is a figure showing the FITC-BSA release profile of the bone tissue regeneration-inducing membrane of the present invention. Figure 10 is a figure showing the BMP-2 release profile of the membrane for inducing bone tissue regeneration according to the present invention. Figure 11 is a figure showing the bone regeneration effect of the bone tissue regeneration-inducing membrane of the present invention. FIG. 12 is a schematic diagram showing a surgical procedure using the bone tissue regeneration-inducing membrane of the present invention. FIG. 13 is a schematic diagram showing the process of releasing BMP-2 in the body using the bone tissue regeneration-inducing membrane of the present invention. Specific details for implementing the invention

[0023] The terms used in this specification have been selected based on currently widely used general terms whenever possible, taking into account their functions in the present invention; however, these terms may vary depending on the intent of those skilled in the art, case law, the emergence of new technologies, etc. Additionally, in specific cases, terms have been arbitrarily selected by the applicant, and in such cases, their meanings will be described in detail in the relevant description of the invention. Therefore, the terms used in this invention should be defined not merely by their names, but based on their meanings and the overall content of the invention.

[0024] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the present invention pertains. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.

[0025] Numerical ranges include the values ​​defined in the above ranges. All maximum numerical limits given throughout this specification include all lower numerical limits as clearly written. All minimum numerical limits given throughout this specification include all higher numerical limits as clearly written. All numerical limits given throughout this specification will include all better numerical ranges within a wider numerical range, as clearly written.

[0027] The present invention will be described in detail below.

[0029] The present invention can provide a method for manufacturing a membrane for inducing bone tissue regeneration. The membrane for inducing bone tissue regeneration according to the present invention can be utilized in guided bone regeneration (GBR).

[0031] The method for manufacturing a membrane for inducing bone tissue regeneration according to the present invention may include the steps of: preparing an electrospinning solution; electrospinning the electrospinning solution onto a membrane to produce an alginate-catechol membrane; immersing the alginate-catechol membrane in a calcium chloride solution to produce an alginate-catechol membrane cross-linked with calcium ions; and coating a protein onto the alginate-catechol membrane cross-linked with calcium ions.

[0033] In the step of preparing the above electrospinning solution, the electrospinning solution may comprise alginate modified with catechol functional groups (Alginate-catechol, Alg-Ca); polyethylene oxide; ethanol; and Triton X-100.

[0034] The above electrospinning solution may be characterized by comprising, for every 0.2 parts by weight of polyethylene oxide, 0.1 to 4 parts by weight of catechol functional group modified alginate; 2 to 12 parts by weight of ethanol; and 0.1 to 1 part by weight of Triton X-100; preferably, for every 0.2 parts by weight of polyethylene oxide, 0.1 to 3 parts by weight of catechol functional group modified alginate; 6 to 10 parts by weight of ethanol; and 0.3 to 0.8 parts by weight of Triton X-100; more preferably, for every 0.2 parts by weight of polyethylene oxide, 1 to 3 parts by weight of catechol functional group modified alginate; 7 to 9 parts by weight of ethanol; and 0.4 to 0.6 parts by weight of Triton X-100.

[0035] The step of preparing the electrospinning solution may be characterized by stirring the electrospinning solution at 32 to 42°C for 12 to 36 hours, preferably at 34 to 40°C for 18 to 30 hours, and more preferably at 36 to 38°C for 22 to 26 hours.

[0037] The method for preparing the above-mentioned catechol functional group modified alginate (Alginate-catechol, Alg-Ca) may include the steps of: dissolving alginate in an MES buffer solution to prepare an alginate solution; dropping EDC solution and NHS solution into the alginate solution to prepare a first reaction product; dropping dopamine solution into the first reaction product to prepare a second reaction product; and dialyzing the second reaction product to prepare the catechol functional group modified alginate.

[0039] The step of manufacturing the above alginate-catechol membrane may be characterized by electrospinning the above electrospinning solution onto the membrane to manufacture the alginate-catechol membrane.

[0040] The step of preparing the alginate-catechol membrane above may involve electrospinning the electrospinning solution using a needle, and the spinning distance may be 10 to 20 cm. Preferably, the spinning distance may be 11 to 19 cm, 12 to 18 cm, or 13 to 17 cm, and more preferably, the spinning distance may be 14 to 16 cm.

[0041] The step of preparing the alginate-catechol membrane above may be characterized by electrospinning the electrospinning solution at a flow rate of 0.1 to 1 mL / h, preferably at a flow rate of 0.1 to 0.9 mL / h, 0.2 to 0.8 mL / h, 0.3 to 0.7 mL / h, or 0.4 to 0.6 mL / h, and more preferably at a flow rate of 0.45 to 0.55 mL / h.

[0042] The step of preparing the above alginate-catechol membrane may be characterized by electrospinning the above electrospinning solution at a voltage of 15 to 25 kV, preferably at a voltage of 17 to 24 kV, and more preferably at a voltage of 18 to 22 kV.

[0043] The step of preparing the alginate-catechol membrane above may be characterized by electrospinning at a temperature of 21 to 31°C, preferably at a temperature of 22 to 30°C, 23 to 29°C, or 24 to 28°C, and more preferably at a temperature of 25 to 27°C.

[0044] The step of preparing the alginate-catechol membrane above may be characterized by electrospinning under conditions of 25 to 45% relative humidity, preferably by electrospinning under conditions of 26 to 44%, 27 to 43%, 28 to 42%, 29 to 41%, 30 to 40%, 31 to 39%, 32 to 38%, or 33 to 37% relative humidity, and more preferably by electrospinning under conditions of 34 to 36%.

[0046] The step of preparing the alginate-catechol membrane cross-linked with calcium ions may further include the step of immersing the alginate-catechol membrane in ethanol; the step of immersing the membrane immersed in ethanol in a calcium chloride solution; and the step of washing the membrane immersed in the calcium chloride solution.

[0048] The step of immersing the alginate-catechol membrane in ethanol may be characterized by immersing the alginate-catechol membrane in ethanol for 1 second to 5 minutes, preferably by immersing the alginate-catechol membrane in ethanol for 30 seconds to 3 minutes, and more preferably by immersing the alginate-catechol membrane in ethanol for 30 seconds to 2 minutes.

[0050] In the step of immersing the membrane immersed in the above ethanol into a calcium chloride solution, the calcium chloride solution may be a solvent mixed with ethanol and distilled water in a volume ratio of 1:3 to 7, preferably a solvent mixed with ethanol and distilled water in a volume ratio of 1:4 to 6, and more preferably a solvent mixed with ethanol and distilled water in a volume ratio of 1:4.5 to 5.5.

[0051] The solution of calcium chloride (CaCl2) mixed in a solvent mixed in a volume ratio of 1:3 to 7 of ethanol and distilled water may be characterized by mixing calcium chloride at a concentration of 0.1 to 4 wt% in the solvent mixed in a volume ratio of 1:3 to 7 of ethanol and distilled water, preferably by mixing calcium chloride at a concentration of 1 to 3 wt% in the solvent mixed in a volume ratio of 1:3 to 7 of ethanol and distilled water, and more preferably by mixing calcium chloride at a concentration of 1.5 to 2.5 wt% in the solvent mixed in a volume ratio of 1:3 to 7 of ethanol and distilled water.

[0053] The step of washing the membrane immersed in the calcium chloride solution above may be characterized by washing the membrane immersed in the calcium chloride solution with one or more solvents selected from the group consisting of distilled water and methanol.

[0054] The step of washing the membrane immersed in the above calcium chloride solution; is the Ca prepared by immersing in the above calcium chloride solution. 2+This may be a step of washing the cross-linked alginate-catechol membrane, and preferably the Ca 2+ The method may further include the step of washing the cross-linked alginate-catechol membrane with distilled water; the step of immersing the membrane washed with distilled water in methanol and ultrasonically treating it; and the step of washing the ultrasonically treated membrane with distilled water.

[0055] The above Ca 2+ The step of washing this cross-linked alginate-catechol membrane with distilled water; is the above Ca 2+ This cross-linked alginate-catechol membrane may be characterized by washing it with distilled water 1 to 5 times, preferably 2 to 4 times, and more preferably 3 times.

[0056] The step of immersing the membrane washed with distilled water in methanol and ultrasonically treating it may be intended to remove polyethylene oxide (PEO) remaining on the membrane washed with distilled water. The step of immersing the membrane washed with distilled water in methanol and ultrasonically treating it may be characterized by immersing the membrane washed with distilled water in methanol and ultrasonically treating it for 10 to 50 minutes, preferably for 20 to 40 minutes, and more preferably for 25 to 35 minutes.

[0057] The step of washing the ultrasonically treated membrane with distilled water may be characterized by washing the ultrasonically treated membrane with distilled water 1 to 5 times, preferably 2 to 4 times, and more preferably 3 times.

[0059] Finally, the above-mentioned washed membrane can be freeze-dried and used.

[0061] The step of coating a protein on the calcium ion-crosslinked alginate-catechol membrane may be characterized by coating one or more proteins selected from the group consisting of BMP-2 (Bone morphogenetic protein-2); BSA (Bovine serum albumin); HSA (Human serum albumin); Gelatin; Fluorescein isothiocyanate (FITC) conjugated protein; and FITC conjugated BSA; and preferably, the calcium ion-crosslinked alginate-catechol membrane may be characterized by coating the BMP-2 (Bone morphogenetic protein-2) protein.

[0062] The step of coating a protein on the calcium ion-crosslinked alginate-catechol membrane may be characterized by reacting a solution containing a protein with the calcium ion-crosslinked alginate-catechol membrane to coat the protein.

[0063] More specifically, the solution containing protein may be reacted with the calcium ion-crosslinked alginate-catechol membrane at 1 to 7°C for 1 to 7 hours, preferably the solution containing protein may be reacted with the calcium ion-crosslinked alginate-catechol membrane at 2 to 6°C for 2 to 6 hours, and more preferably the solution containing protein may be reacted with the calcium ion-crosslinked alginate-catechol membrane at 3 to 5°C for 3 to 5 hours.

[0064] The above protein may be one or more proteins selected from the group consisting of BMP-2 (Bone morphogenetic protein-2); BSA (Bovine serum albumin); HSA (Human serum albumin); Gelatin; Fluorescein isothiocyanate (FITC) conjugated protein; and FITC conjugated BSA; and preferably, it may be BMP-2 (Bone morphogenetic protein-2); or FITC conjugated BSA.

[0065] The solution containing the protein may be a solution in which the protein is dissolved at a concentration of 0.01 to 0.09 μg / mL.

[0067] The embodiments of the present invention are described in detail below, but it is obvious that the present invention is not limited by the following embodiments.

[0069] Example 1. Ca 2+ Preparation of cross-linked alginate-catechol membranes

[0071] 1-1. Preparation of Alginate-Catechol Membranes

[0072] Alginate modified with catechol functional groups was synthesized via an EDC / NHS-mediated binding reaction. First, a 0.1 M MES buffer solution was prepared, and the pH was adjusted to 5.2 using a 1 M sodium hydroxide solution and 1 M hydrochloric acid. 1 g (5 mmol) of alginate was added to 80 mL of the prepared 0.1 M MES buffer solution at pH 5.2, and the alginate was completely dissolved by high-speed stirring using a magnetic stirrer. While the alginate was dissolving, 5 mmol of EDC and 5 mmol of NHS were dissolved in 10 mL of the MES buffer solution, respectively, and stirred until completely dissolved. Subsequently, nitrogen (N2) gas was injected into each solution for 10 minutes to remove dissolved oxygen. After the nitrogen injection was finished, the previously prepared EDC and NHS solutions were added to the alginate solution by dropwise injection, and nitrogen gas was injected again for 5 minutes. Subsequently, a dopamine solution was prepared by dissolving 5 mmol of dopamine in 3 mL of MES buffer. The prepared dopamine solution was added to the reaction solution via drip infusion, followed by the injection of nitrogen gas for 5 minutes. After the nitrogen injection was completed, the top of the rubber stopper was sealed with Parafilm to prevent gas leakage, and the reaction was carried out at room temperature for 1 hour. After the reaction was complete, 20 g of sodium chloride was dissolved in 5 L of distilled water for dialysis, and the pH was adjusted to 6 using 1 M sodium hydroxide solution and 1 M hydrochloric acid. The reaction solution was placed in a dialysis membrane and immersed in the aforementioned pH 6 distilled water to perform dialysis. Dialysis was performed for 4 hours after the initial 30 minutes, with the solution replaced with fresh pH 6 distilled water; this process was repeated a total of 4 times. Subsequently, dialysis was performed for an additional 4 hours in distilled water that did not contain sodium chloride. Finally, the dialysis-completed alginate-catechol solution was recovered from the dialysis membrane and transferred to a conical tube for centrifugation, and then alginate modified with catechol functional groups was obtained through freeze-drying.

[0074] 2 wt% of the obtained alginate-catechol (Alg-Ca) modified with catechol functional groups, 0.2 wt% of polyethylene oxide (PEO), 8 wt% of ethanol, and 0.5 wt% of Triton X-100 were mixed with distilled water and stirred at 37°C for 24 hours to prepare an electrospinning solution. The electrospinning solution was electrospun onto aluminum foil to produce an alginate-catechol membrane. More specifically, the electrospinning solution was injected into a Luer-lock syringe and fitted with a 20G metal needle, with the distance between the needle and the collector maintained at 15 cm. The injection flow rate of the electrospinning solution was set to 0.5 mL / h, and the electrospinning environment was maintained at a temperature of 26°C and a relative humidity of 35%. The voltage was gradually increased to form nanofibers in the range of 18–22 kV, which were then recovered from the collector.

[0076] 1-2. Ca 2+ Preparation of cross-linked alginate-catechol membranes

[0077] The alginate-catechol membrane prepared by the same method as in Example 1-1 above was immersed in ethanol for 1 minute, and then the membrane immersed in ethanol was immersed in a calcium chloride solution for 10 seconds to crosslink the alginate with calcium ions. The calcium chloride solution was prepared by mixing 2 wt% calcium chloride (CaCl2) with a solvent consisting of ethanol and distilled water in a volume ratio of 1:5. The membrane immersed in the calcium chloride solution was washed three times with distilled water to remove residual calcium ions. In addition, to remove residual polyethylene oxide (PEO), the membrane was immersed in methanol, subjected to sonication for 30 minutes, and washed again three times with distilled water. The membrane, after all washing was completed, was freeze-dried, and Ca 2+ A cross-linked alginate-catechol membrane was prepared.

[0078] Ca of Example 1 2+The method for preparing a cross-linked alginate-catechol membrane is schematically illustrated in Fig. 1.

[0080] Example 2. Ca 2+ BMP-2 protein coating on cross-linked alginate-catechol membranes

[0081] The Ca prepared in Example 1 above 2+ BMP-2 growth factor protein was coated on the surface of a cross-linked alginate-catechol membrane. More specifically, the membrane of Example 1 was cut into equal sizes using a 6 mm puncher and placed in a 96-well plate. Subsequently, BMP-2 protein was dissolved in 0.1 M Tris buffer (pH 8.5) at a concentration of 0.05 μg / mL, 200 μL was dispensed into each well, and the membrane was coated at 4°C for 4 hours. The membrane coated with BMP-2 was washed three times with distilled water to remove unreacted material.

[0083] Comparative Example 1. Preparation of an alginate membrane

[0084] An electrospinning solution was prepared by mixing 1.8 wt% alginate (Alg), 0.2 wt% polyethylene oxide (PEO), 6.5 wt% ethanol, and 0.6 wt% Triton X-100 in distilled water and stirring at 37°C for 24 hours. An alginate membrane was prepared by electrospinning the solution onto aluminum foil. More specifically, the electrospinning solution was injected into a Luer-lock syringe and fitted with a 20G metal needle, with the distance between the needle and the collector maintained at 14 cm. The injection flow rate of the electrospinning solution was set to 0.5 mL / h, and the electrospinning environment was maintained at a temperature of 26°C and a relative humidity of 35%. The voltage was gradually increased to form nanofibers in the range of 18–22 kV, which were then recovered from the collector.

[0086] Comparative Example 2. Ca 2+ Preparation of cross-linked alginate membranes

[0087] An alginate membrane was prepared using the same method as in Comparative Example 1 above, and the alginate membrane was prepared using Ca in the same method as in Example 1-2 above. 2+ By cross-linking calcium ions, Ca 2+ Cross-linked alginate membrane (Alg +Ca 2+ Manufactured ).

[0089] Comparative Example 3. Preparation of an alginate-catechol membrane

[0090] An alginate-catechol membrane (Alg-Ca MEM) was prepared using the same method as in Example 1-1 above.

[0092] Experimental Example 1. Ca 2+ SEM image analysis of cross-linked alginate-catechol membranes

[0093] The Ca prepared in Example 1 above 2+ SEM images of the cross-linked alginate-catechol membrane were observed. More specifically, the bilateral structure of the membrane was observed using a scanning electron microscope (SEM). SEM analysis was performed using a Hitachi SU8220 (Hitachi High-Tech, Japan) instrument under an acceleration voltage of 5 × 10 kV. To ensure the conductivity of the sample, a platinum (Pt) coating was applied once using an E-1030 ion sputter coater (Hitachi High-Tech, Japan), and the measured results were analyzed using ImageJ software. The results of Experimental Example 1 are shown in Figure 2.

[0094] Referring to Figure 2, it was observed that the electrospun nanofibers had a continuous fiber form with a diameter of approximately 58 ± 12 nm, and that a film was manufactured with a uniform shape without bead formation.

[0096] Experimental Example 2. FT-IR Analysis Results of Membrane Components

[0097] The chemical structures of the alginate-catechol (Alg-Ca), polyethylene oxide washed alginate-catechol (PEO wash Alg-Ca), polyethylene oxide (PEO), and a mixture of alginate-catechol and polyethylene oxide mixed in a 9:1 ratio (Alg-Ca:PEO (9:1)) constituting the membrane prepared in Example 1 above were analyzed by FT-IR.

[0098] Fourier-transform infrared spectroscopy (FT-IR) was performed on both sides of the polymer powder and electrospun multilayer mat, using a PerkinElmer Frontier FT-IR spectrometer (PerkinElmer Inc., USA) in attenuated total reflectance (ATR) mode, and the FT-IR spectra ranged from 400 to 4000 cm⁻¹. -1 It was collected in the wavelength range. The results of Experimental Example 2 above are shown in Fig. 3.

[0099] Referring to Fig. 3, for the PEO single component, approximately 2880 cm⁻¹ -1 (CH stretching), 1112 cm -1 A characteristic peak of (COC stretching) appeared, and in Alg-Ca, it was 1610 cm⁻¹. -1 (C=O), 1410 cm -1 A peak of (C-OH) was observed. In the spectrum of the Alg-Ca:PEO mixture (9:1), the main peaks of the two materials coexisted, and after the removal of PEO, the intensity of the PEO-specific peak in Alg-Ca decreased, confirming that the cleaning was effective. The results of Experimental Example 2 above can structurally support the change in membrane composition and the post-treatment process.

[0101] Experimental Example 3. Ca 2+ Analysis of Mechanical Properties of Cross-linked Alginate-Catechol Membranes

[0103] 3-1. Tensile Strength Analysis

[0104] In Experimental Example 3-1, the Ca of Example 1 2+ Cross-linked alginate-catechol membrane, alginate membrane of Comparative Example 1, Ca of Comparative Example 2 2+ The tensile strength of a cross-linked alginate membrane, the alginate-catechol membrane of Comparative Example 3, and a commercially available alginate membrane was analyzed. Each membrane was prepared by manufacturing it in the same manner as in Example 1 and Comparative Examples 1 to 3.

[0105] Next, tensile strength was evaluated using a universal testing machine (MCT-2150, A&D Company, Japan). Specimens were cut according to ASTM D638 standards, and the test was performed at room temperature. Young's modulus, tensile strength, and elongation at break were analyzed from the stress-strain curves obtained from the tensile test. All measurements were repeated five times under the same conditions, and the results of Experimental Example 3-1 are shown in Fig. 4A.

[0106] Referring to FIG. 4A, the Ca of Comparative Examples 1 and 3 above 2+ The Alg and Alg-Ca membranes not cross-linked with ions exhibited tensile strengths of 10.5 ± 1.2 MPa and 11.2 ± 0.8 MPa, respectively. On the other hand, the Ca of Example 1 above 2+ The cross-linked Alg-Ca membrane showed a significantly improved tensile strength of 44.7 ± 5.6 MPa, which was also significantly higher than that of commercial alginate membranes. These results suggest that the double cross-linking structure caused by metal ions of catechol groups strengthens the mechanical properties of the membrane.

[0108] 3-2. Structural Stability Assessment

[0109] In Experimental Example 3-1, the Ca of Example 1 2+ Cross-linked alginate-catechol membrane, alginate membrane of Comparative Example 1, Ca of Comparative Example 22+ The structural stability of the cross-linked alginate membrane and the alginate-catechol membrane of Comparative Example 3 was evaluated by analyzing the degree of weight loss. Each membrane was prepared by manufacturing it in the same manner as in Example 1 and Comparative Examples 1 to 3.

[0110] Next, the membranes were cut into uniform 1×1 cm squares, and their weights were measured in a dry state. Each membrane was individually placed in 3 x 1 / 2 mL of PBS, placed in a Petri dish, sealed with Parafilm, and incubated at 37°C. After completely removing the PBS at set time intervals, the membranes were stored in a freezer for 30 minutes and then freeze-dried; the remaining dry weight was measured in a completely dry state. This process was repeated for 70 days to analyze the degradation pattern over time, and the degree of weight loss of the membranes was calculated using Equation 1 below. The results of Experimental Example 3-2 are shown in Fig. 4B.

[0111] Referring to FIG. 4B, the Ca of Comparative Examples 1 and 3 above 2+ Alg and Alg-Ca membranes not cross-linked with ions exhibited rapid degradation of over 90% within one day, which implies very low physical stability. On the other hand, the Ca of Example 1 above 2+ The Alg-Ca membrane cross-linked with [the material] degraded slowly to less than 50% during the initial 5 days, and maintained about 70% of its mass even at the 60-day mark. Therefore, it was confirmed that the membrane of Example 1 had superior structural stability compared to the membranes of Comparative Examples 1 to 3.

[0113] [Equation 1]

[0114] Weight loss (%) = (W0 - W t ) / W0× 100

[0116] Experimental Example 4. Ca 2+ Analysis of Cytocompatibility and Osteogenesis Inducibility of Cross-linked Alginate-Catechol Membranes

[0118] 4-1. Cell Viability Analysis

[0119] In Experimental Example 4-1, the Ca of Example 1 2+ Cross-linked alginate-catechol membrane, Ca of Comparative Example 2 2+ Cell viability was analyzed using the CCK-8 assay when treated with cross-linked alginate membranes and a control group.

[0120] More specifically, each membrane sample was added to α-MEM medium at a concentration of 0.5 mg / mL, and extraction was carried out at 37°C for 24 hours. The extract was used for cell culture, and MC3TT3-E1 cells were seeded in a 96-well plate, treated with the extract, and cultured for 24 hours. Subsequently, 10 μL of CCK-8 solution was added to each well and reacted for 2 hours, after which the absorbance was measured at a wavelength of 450 nm using a microplate reader (Infinite 200 Pro, Tecan, Switzerland). The results of Experimental Example 4-1 are shown in Fig. 5A.

[0121] Referring to Fig. 5A, it was confirmed that the membrane of Example 1 showed a significantly higher cell viability compared to the membrane of Comparative Example 2 and the control group. Therefore, the Ca of Example 1 2+ Cross-linked alginate-catechol membranes are biocompatible with Ca 2+ It was confirmed to be superior compared to the cross-linked alginate membrane and the control group.

[0123] 4-2. Alkaline Phosphate (ALP) Activity Analysis

[0124] The ALP activity of the Ca2+ cross-linked Alg-Ca membrane of Example 1 and the Ca2+ cross-linked Alg membrane of Comparative Example 2 was analyzed with and without BMP-2 coating. BMP-2 coating was applied to the membrane in the same manner as in Example 2.

[0125] Each membrane was added to OSM at a concentration of 0.5 mg / mL, and extracts were prepared by performing extraction at 37°C for 24 hours. The extracts were applied to MC3T3-E1 cells for 7 days to induce osteogenic differentiation. After 7 days, the cells were washed with PBS and lysed in lysis buffer, and ALP activity was measured at a wavelength of 405 nm using an ALP assay kit. Absorbance measurements were performed using an Infinite 200 Pro M Plex microplate reader (Tecan, M It was performed using (Nnedorf, Switzerland). The results of Experimental Example 4-2 are shown in Fig. 5B.

[0126] Referring to Figure 5B, Alg-Ca and Alg membranes not coated with BMP-2 showed high ALP activity, which implies the potential for inducing spontaneous osteodifferentiation. On the other hand, when coated with BMP-2, no significant difference was observed between the membranes.

[0128] 4-3. Analysis of Gene Expression Related to Bone Formation and Angiogenesis

[0129] The Ca2+ cross-linked Alg-Ca membrane of Example 1 and the Ca2+ cross-linked Alg membrane of Comparative Example 2 were prepared by coating them with BMP-2. The BMP-2 coating method was carried out in the same manner as in Example 2. The membranes were added to α-MEM medium at a concentration of 0.5 mg / mL, and an extract was prepared by performing extraction at 37°C for 24 hours. After treating MC3T3-E1 cells with the extract for 24 hours, the cells were washed with PBS, and total RNA was extracted using TRIzol™ reagent (Invitrogen, MA, USA). The extracted RNA was reverse transcribed into cDNA using the PrimeScript 1st strand cDNA Synthesis Kit (Takara Bio, Shiga, Japan). Gene expression was performed using the CFX Duet Real-Time PCR System (Bio-Rad, CA, USA) with AccuPower® 2X GreenStar™ qPCR Master Mix (BIONEER, Daejeon, South Korea). The relative expression levels of each gene were normalized using β-actin as the endogenous control gene, and 2 (-ΔΔCt) It was analyzed using the method.

[0130] The results of Experimental Example 4-3 above are shown in Fig. 5C, and the genes analyzed in Experimental Example 4-3 are Runx2, Sp7, Bglap, Osteopontin, Smad1, VEGF, IL-6 and TGF-β1.

[0131] Referring to Fig. 5C, Alg-Ca(+Ca) coated with BMP-2 2+In the group, the expression of Runx2, Sp7, Bglap, Osteopontin, Smad1, and VEGF genes was significantly increased. In particular, VEGF, a key factor related to the promotion of angiogenesis, showed a difference in expression at the p < 0.0001 level. On the other hand, there was no statistically significant difference in the expression of IL-6 and TGF-β1. Since IL-6 and TGF-β1 are representative inflammation-related genes, the fact that there was no change in the expression of these genes suggests that the membrane of the present invention did not induce an inflammatory response.

[0133] 4-4. Analysis of Bone Formation-Related Protein Expression

[0134] The Ca2+ cross-linked Alg-Ca membrane of Example 1 and the Ca2+ cross-linked Alg membrane of Comparative Example 2 were prepared by coating them with BMP-2. The BMP-2 coating method was carried out in the same manner as in Example 2. The membranes were added to α-MEM medium at a concentration of 0.5 mg / mL, and extraction was performed at 37°C for 24 hours to prepare the extract. After treating MC3T3-E1 cells with the extract for 24 hours, the cells were washed with PBS and recovered using a cell scraper. Subsequently, proteins were extracted using RIPA buffer. Protein expression was confirmed by performing gn Western blot analysis on the extracted proteins separated via SDS-PAGE. The relative expression levels of each protein were normalized using β-actin as the endogenous control protein and quantified using the Chemidoc system.

[0135] The results of Experimental Example 4-4 above are shown in Fig. 5D, and the antibodies analyzed in Experimental Example 4-4 above are Runx2, Phospho-Smad1 / 5, COL1A1, and Osteopontin.

[0136] Referring to Figure 5D, the expression of Runx2, Phospho-Smad1 / 5, COL1A1, and Osteopontin proteins was significantly increased in the Alg-Ca(+Ca2+) group coated with BMP-2. In particular, the expression of COL1A1, a key factor related to ECM formation, showed a difference in expression at the p < 0.001 level.

[0138] To summarize the results of Experimental Examples 4-1 to 4-4 above, the separation membrane of the present invention exhibits excellent cell affinity and bone regeneration inducing ability, and in particular Ca 2+ It was confirmed that these effects were enhanced through cross-linking and that the product could be applied in vivo without inducing an inflammatory response.

[0140] Experimental Example 5. Analysis of protein adsorption rate according to coating protein type

[0142] 5-1. Protein Adsorption Rates upon BSA, HSA, and Gelatin Coating

[0143] In Experimental Example 5-1, BSA, HSA, and gelatin were coated onto a membrane, and the adsorption rate over time was analyzed using a BCA assay. More specifically, the experiment was conducted by coating the Alg-Ca membrane of Example 1-1 and the Alg membrane of Comparative Example 1 with BSA, HSA, and gelatin, respectively. The protein coating method was carried out in the same manner as in Example 2. The results of Experimental Example 5-1 are shown in Fig. 6.

[0144] Referring to Fig. 6, the Alg-Ca membrane of Example 1-1 showed faster and higher adsorption efficiency for all types of proteins compared to the Alg membrane of Comparative Example 1. In addition, since the adsorption rate for most proteins reached a maximum within 4 hours, 4 hours was determined to be the optimal protein coating time.

[0146] 5-2. Protein Adsorption Rate When Coated with FITC-BSA

[0147] Ca of Example 1 above 2+ The cross-linked Alg-Ca membrane and the Ca of Comparative Example 2 above 2+FITC-BSA was immobilized on the surface of a cross-linked Alg film and observed using a fluorescence microscope. More specifically, the Ca of Example 1 above 2+ The cross-linked Alg-Ca membrane and the Ca of Comparative Example 2 above 2+ The cross-linked Alg membrane was cut into uniform sizes of 1×1 cm and placed in a 24-well plate. FITC-BSA was dissolved in 0.1 M Tris buffer (pH 8.5) at a concentration of 0.5 mg / mL, and 1 mL was added to each well and reacted at 4°C for 4 hours. Afterward, the mixture was washed three times with distilled water to remove any remaining unreacted material. The results of Experimental Example 5-2 are shown in Fig. 7.

[0148] Referring to FIG. 7, compared to the separator of Comparative Example 2, the Ca of Example 1 2+ Stronger and more uniform fluorescence was observed when FITC-BSA was immobilized on a cross-linked Alg-Ca membrane. This is because Ca 2+ This suggests that cross-linked Alg-Ca membranes have superior protein adsorption capacity.

[0150] Experimental Example 6. Ca 2+ Analysis of kinase activity of cross-linked alginate-catechol membranes

[0151] Ca of Example 1 above 2+ The cross-linked Alg-Ca membrane and the Ca of Comparative Example 2 above 2+ After loading the kinase protein onto the cross-linked Alg membrane, the kinase activity was measured. More specifically, the membrane samples were distributed in equal sizes into a 24-well plate. The kinase was dissolved in 0.1 M Tris buffer (pH 8.5) at a concentration of 0.1 mg / mL, and 60 μL of the dissolved solution was added to each well and reacted for 1 hour. After washing three times with distilled water, 2 mL of 15 mM pNPP solution was added to each well, and the absorbance was measured at 405 nm at 5-minute intervals for a total of 40 minutes. The results of Experimental Example 6 are shown in Fig. 8.

[0152] Referring to FIG. 8, the Ca of Example 1 above 2+ The highest kinase activity was observed in the cross-linked Alg-Ca membrane. Since this implies that the kinase protein was immobilized on the membrane while maintaining its biological activity, the membrane of the present invention can immobilize proteins while stably maintaining their biological activity.

[0154] Experimental Example 7. Ca 2+ Protein release from cross-linked alginate-catechol membranes

[0156] 7-1. FITC-BSA Emission Profile

[0157] Ca of Example 1 above in the same manner as Experimental Example 5-2 above 2+ The cross-linked Alg-Ca membrane and the Ca of Comparative Example 2 above 2+ FITC-BSA was immobilized on the surface of a cross-linked Alg membrane. The FITC-BSA protein release profile of the FITC-BSA immobilized membrane was measured. More specifically, 1 mL of PBS was added to each well of the membrane, and release experiments were conducted at regular time intervals while stirring with a stirrer at 37°C and 50 rpm. At each time point, 200 μL of the supernatant was collected to measure fluorescence intensity, and the same volume of PBS (200 μL) was replenished to match the collected amount, and the experiment was repeated until the end. The results of Experimental Example 7-1 are shown in Fig. 9.

[0158] Referring to FIG. 9, the Ca of Example 1 above 2+ Although the cross-linked Alg-Ca membrane carried more FITC-BSA protein than the membrane of Comparative Example 2, the initial burst release was suppressed, and it exhibited a more gradual and progressive release pattern. This is in contrast to the Ca of Example 1. 2+ This means that in cross-linked Alg-Ca membranes, proteins are stably distributed within and on the surface of the membrane, and the release rate is controlled by the cross-linked structure.

[0159] Therefore, the Ca of the present invention 2+ Cross-linked Alg-Ca membranes are considered a suitable system for biomedical environments requiring continuous delivery without excessive initial release.

[0161] 7-2. BMP-2 Emission Profile

[0162] Ca of Example 1 in the same manner as Example 2 above 2+ BMP-2 was immobilized on the surface of a cross-linked Alg-Ca membrane. Next, the release pattern of BMP-2 was measured by ELISA. More specifically, for the quantification of Hif-1α in MC3T3-E1 cells, 100 μg of total protein per well was used with the Human / Mouse Total HIF-1α / HIF1A Kit (R&D Systems, MN, USA). Absorbance was measured using a microplate reader (Infinite 200 Pro, Tecan, M It was measured at 450 nm after correction at 540 nm using (Nnedorf, Switzerland). The results of Experimental Example 7-2 above are shown in Fig. 10.

[0163] Referring to FIG. 10, the Ca immobilized with BMP-2 of Example 2 2+ An initial burst release phenomenon was observed in the cross-linked Alg-Ca membrane, with approximately 70% of BMP-2 released within 24 hours, followed by gradual additional release up to 120 hours. That is, the Ca of the present invention 2+ Cross-linked Alg-Ca membranes can be utilized as a platform to control the release of physiologically active proteins.

[0165] Experimental Example 8. Ca 2+ Bone regeneration effect of cross-linked alginate-catechol membrane

[0167] 8-1. Micro-CT Scanning

[0168] In a mouse model with induced skull microtissue defects, coated with the BMP-2 of Example 2 and Ca2+ The bone regeneration effect of cross-linked alginate-catechol membrane treatment was verified using Micro-CT.

[0169] All experiments were conducted in accordance with the guidelines approved by Kyungpook National University (Approval No. 2024-0091). Seven-week-old male C57BL / 6 mice were purchased from Hyochang Science. Nine C57BL / 6 mice were divided into three groups, placed in separate cages, and provided with an acclimatization period of one week prior to surgery. 0.25 g of 2,2,2-Tribromoethanol and 0.5 mL of 2-Methyl-2-butanol were mixed and completely dissolved at 37°C, after which sterile distilled water was added to make a total volume of 20 mL. 0.35 mL of the prepared anesthetic was injected intraperitoneally into each mouse. Once anesthetized, the hair was secured with 70% EtOH, a 1.5 cm incision was made down the midline of the scalp, and a defect was created on the left side of the skull using a 5 mm diameter treffin bur and a dental handpiece. Subsequently, the scalp was sutured with sutures (REXSIL Silk, SM ENG). A group with a defect created and no treatment was selected as the negative control (Sham), and a group administered 2 μL of BMP-2 to the defect site was selected as the control (BMP-2 only). Additionally, a group with only a Ca²⁻⁺ cross-linked alginate-catechol membrane without BMP-2 attached to the defect site was designated as the Alg-Ca MEM group. The experimental group had a membrane loaded with BMP-2 attached to the defect site. Mice were housed under a 12-hour light-dark cycle at approximately 22°C and provided with sufficient tap water and a standard laboratory diet throughout the experiment.

[0170] The mouse model above underwent a recovery period of one month after surgery and was euthanized to obtain bone samples. The skull was detached and fixed in a 10% formalin solution for 24 hours. The samples were imaged using micro-CT (SKYSCAN1272 ex-vivo micro-CT). Images of the repaired bone were visualized through micro-CT imaging. The results of Experimental Example 8-1 are shown in Fig. 11A.

[0171] Referring to Fig. 11A, bone regeneration at the defect site was induced only very restrictively in the control group (Sham), Alg-Ca MEM, and BMP-2 alone treatment groups, whereas the BMP-2 coated with Ca of Example 2 above and Ca 2+ In the group treated with a cross-linked alginate-catechol membrane, distinct bone regeneration was observed to the extent that the defect site was almost completely filled.

[0173] 8-2. Masson's Trichrome (MT) Staining

[0174] After the Micro CT evaluation of Experimental Example 8-1, all skull specimens were observed using Masson Trichrome staining. More specifically, the skull specimens were fixed in a 4% formalin solution for 7 days and then demineralized in 10% ethylenediaminetetraacetic acid (EDTA). The demineralized samples were dehydrated, captured in paraffin, and then cut into 3 μm thick slices. Subsequently, the formation of new bone and the effect of scaffold material implantation were observed using Masson Trichrome staining. The results of Experimental Example 8-2 are shown in Fig. 11B.

[0175] Referring to FIG. 11B, the BMP-2 of Example 2 is coated with Ca 2+ In the group treated with a cross-linked alginate-catechol membrane, the formation of dense and continuous collagen-based neoplastic tissue along the defect site was observed. Furthermore, the neoplastic tissue exhibits distinct bone tissue characteristics rather than fibrotic tissue.

[0177] 8-3. Quantitative Analysis of Bone Formation Rate and Residual Defect Area

[0178] Based on the results of Experimental Examples 8-1 and 8-2 above, the bone formation rate and residual defect area of ​​the mouse models for each treatment group were quantitatively analyzed. The results of the quantitative analysis of the bone formation rate are shown in Fig. 11C, and the results of the quantitative analysis of the residual defect area are shown in Fig. 11D.

[0179] Referring to Figure 11C, the bone formation rate was significantly increased to over 27% in the Alg-Ca + BMP-2 group.

[0180] Referring to Fig. 11D, the residual defect area is approximately 0.15 cm in the Alg-Ca + BMP-2 group. 2 It was measured to be the smallest.

[0181] In other words, since it was confirmed that the Alg-Ca + BMP-2 group exhibited superior bone regeneration ability compared to the BMP-2 alone treatment group and the Alg-Ca MEM group, the Ca of the present invention 2+ Cross-linked alginate-catechol membranes can function as protein carriers and as separation membranes capable of maximizing the bioavailability of BMP-2 and inducing tissue regeneration.

[0183] 8-4. Analysis of Expression Patterns of Markers Related to ECM Formation and Angiogenesis via Immunofluorescence Staining

[0184] Based on the results of Experimental Examples 8-1 and 8-2 above, the degree of ECM formation and angiogenesis in mouse models for each treatment group was compared and analyzed through immunofluorescence staining. Immunofluorescence staining for markers related to ECM formation and angiogenesis was performed on tissue sections obtained from each treatment group, and the expression pattern was observed based on the area and intensity of the fluorescence signal.

[0185] Referring to Figure 11E, the fluorescence signal of the ECM-related marker in the Alg-Ca + BMP-2 treatment group was strongly observed over a wide area compared to other treatment groups, confirming that the formation of ECM in the tissue was induced relatively well.

[0186] Referring to Figure 11F, the fluorescent signals of angiogenesis-related markers in the Alg-Ca + BMP-2 treatment group were distributed relatively uniformly throughout the tissue, suggesting that stable angiogenesis was induced.

[0187] Synthesizing these results, the Alg-Ca + BMP-2 treatment group showed a tendency for ECM formation and angiogenesis to be induced more harmoniously compared to the BMP-2 alone treatment group. This confirmed that the Alg-Ca membrane can enhance the delivery efficiency of BMP-2, thereby providing a microenvironment favorable for bone regeneration. Therefore, the Ca²⁻⁺ cross-linked alginate-catechol membrane of the present invention can function as a membrane capable of enhancing the bioavailability of BMP-2 as a protein carrier and effectively inducing tissue regeneration.

[0189] Experimental Example 9. Analysis of Viscosity and Electrical Conductivity According to Electrospinning Solution Composition

[0190] The composition of the electrospinning solution of Example 1-1 was prepared in various ways as described in Table 1 below, and their viscosity and electrical conductivity were analyzed. The viscosity and electrical conductivity of the electrospinning solution are major factors affecting the stability of the electrospinning process and fiber formation. If the viscosity is excessively high, the flowability of the solution is reduced, which may lead to nozzle clogging or discontinuous spinning; conversely, if the viscosity is too low, the continuity of the jet is not ensured, resulting in increased bead formation. Additionally, if the electrical conductivity is excessively high, jet instability increases, and if it is excessively low, sufficient electrical attraction is not formed, limiting fiber formation.

[0191] Referring to Table 1, the Alg-Ca:EtOH (2:8) + Triton X composition maintains a relatively low viscosity (417.31) while exhibiting appropriate electrical conductivity (3.9066), providing favorable conditions for stable jet formation and fiber stretching. In particular, it is believed that the addition of Triton X reduces the surface tension of the solution, thereby suppressing jet splitting during spinning and enabling more uniform fiber formation.

[0192] On the other hand, in compositions with only Alg-Ca and a low ratio of EtOH, the viscosity is excessively high, which may lead to reduced radiation stability, and in compositions with an excessively high ratio of EtOH (e.g., 1:9 + Triton X), the electrical conductivity is excessively low, which is observed to be a limitation in that sufficient jet driving force is not secured.

[0193] Therefore, the Alg-Ca:EtOH (2:8) + Triton X composition is considered to be the optimal condition in terms of the stability of the electrospinning process and uniform fiber formation, as it exhibits the best balance of viscosity and electrical conductivity.

[0195] furtherance (Composition) electrical conductivity (Conductivity) viscosity (Viscocity) Alg-Ca only 5.3488 351.73 Alg-Ca:EtOH (9:1) 3.4972 447.95 Alg-Ca:EtOH (8:2) 2.376 684.71 Alg-Ca:EtOH (7:3) 1.6896 94.48 Alg-Ca:EtOH (6:4) 1.0436 86.64 Alg-Ca:EtOH (1:1) 0.5646 83.88 Alg-Ca:EtOH (2:8) +TritonX 3.9066 417.31 Alg-Ca:EtOH (1:9)+TritonX 0.4284 205.63

[0197] From the foregoing description, those skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive.

Claims

Claim 1 A step of preparing an alginate solution by dissolving 1 g (5 mmol) of alginate in 80 mL of 0.1 M MES buffer solution at pH 5.2; a step of preparing an EDC solution by dissolving 5 mmol of EDC in 10 mL of MES buffer solution and an NHS solution by dissolving 5 mmol of NHS in 10 mL of MES buffer solution, and preparing a first reaction product by dropwise adding the EDC solution and the NHS solution to the alginate solution; a step of preparing a second reaction product characterized by preparing a dopamine solution by dissolving 5 mmol of dopamine in 3 mL of MES buffer solution and dropwise adding the dopamine solution to the first reaction product to form an amide bond between the carboxyl group of alginate and the amine group of dopamine; a step of preparing an alginate in which the carboxyl group of alginate is modified into a catechol functional group by dialyzing the second reaction product; and an alginate in which the carboxyl group of alginate is modified into a catechol functional group (Alginate-catechol), polyethylene A method for manufacturing a membrane for inducing bone tissue regeneration, comprising: a step of preparing an electrospinning solution comprising oxide, ethanol, and polyoxyethylene octylphenyl ether; a step of electrospinning the electrospinning solution onto a membrane to produce an alginate-catechol membrane; a step of immersing the alginate-catechol membrane in a solution of calcium chloride (CaCl2) mixed with a solvent mixed with ethanol and distilled water to produce an alginate-catechol membrane cross-linked with calcium ions; a step of immersing the alginate-catechol membrane cross-linked with calcium ions in methanol and performing ultrasonic treatment to remove residual polyethylene oxide (PEO) to produce a washed alginate-catechol membrane; and a step of coating the washed alginate-catechol membrane with BMP-2 (Bone morphogenetic protein-2) protein. Claim 2 delete Claim 3 A method for manufacturing a membrane for inducing bone tissue regeneration according to claim 1, wherein the electrospinning solution comprises, for every 0.2 parts by weight of polyethylene oxide, 0.1 to 4 parts by weight of alginate modified with catechol functional groups; 2 to 12 parts by weight of ethanol; and 0.1 to 1 part by weight of polyoxyethylene octylphenyl ether. Claim 4 A method for manufacturing a membrane for inducing bone tissue regeneration according to claim 1, wherein the step of manufacturing the alginate-catechol membrane is characterized by electrospinning the electrospinning solution at a flow rate of 0.1 to 1 mL / h. Claim 5 A method for manufacturing a membrane for inducing bone tissue regeneration according to claim 1, wherein the step of manufacturing the alginate-catechol membrane is characterized by electrospinning the electrospinning solution at a voltage of 15 to 25 kV. Claim 6 A method for manufacturing a membrane for inducing bone tissue regeneration according to claim 1, wherein the step of manufacturing the alginate-catechol membrane is characterized by electrospinning under conditions of a temperature of 21 to 31°C and a relative humidity of 25 to 45%. Claim 7 A method for manufacturing a membrane for inducing bone tissue regeneration according to claim 1, wherein the step of manufacturing the alginate-catechol membrane is characterized by electrospinning at a radiation distance of 10 to 20 cm. Claim 8 A method for manufacturing a membrane for inducing bone tissue regeneration according to claim 1, wherein the step of manufacturing an alginate-catechol membrane cross-linked with calcium ions is characterized by immersing the alginate-catechol membrane in a solution in which calcium chloride (CaCl2) is mixed with a solvent in which ethanol and distilled water are mixed in a volume ratio of 1:3 to 7. Claim 9 delete Claim 10 delete Claim 11 delete

Citation Information

Patent Citations

  • Nonwoven nanofibrous membranes for guiding bone tissue regeneration and their preparation method

    KR1020090071982A

  • Immobilization method of bioactive molecules using polyphenol oxidase

    US20130224795A1